Phase II study of mitoxantrone in unresectable primary hepatocellular carcinoma following hepatitis B infection

Kwok Hung Lai, Yang Te Tsai, Shou Dong Lee, Wai Wah Ng, Ho Chung Teng, Tseng Nip Tam, Gin Ho Lo, Han Chieh Lin, Hwai Jeng Lin, Jaw Ching Wu, Chii Shyan Lay, Sun Sang Wang, Wing Kai Chan

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

A total of 20 patients with histologically proven primary hepatocellular carcinoma (PHC) received mitoxantrone IV at a dose of 10-16 mg/m2 every 3 weeks. All patients had previous hepatitis B infection. None underwent remission after treatment; 2 had stable disease and 18 progressive disease. The median overall survival was 13 weeks (range, 1-59 weeks). There was no evidence of significant antitumor activity for mitoxantrone in our patients with PHC. Hematotoxicity occurred in 100% of the patients with grades 2-4 leukopenia, 89% of those with grades 1-4 anemia, and 26% of those with grades 2-3 thrombocytopenia. Cardiotoxicity occurred in 20% of the patients after 14-30 mg/m2 mitoxantrone; these included complete heart block with fatal outcome in one case, decreased ventricular ejection fraction in one, and sinus tachycardia in two. Nausea, vomiting, fever, diarrhea, and alopecia were mild and occurred in 15%-45% of the patients (Table 3). Therefore, patients with PHC following hepatitis B infection may be less tolerant to mitoxantrone, resulting in the apparent increase in toxicities.

Original languageEnglish
Pages (from-to)54-56
Number of pages3
JournalCancer Chemotherapy and Pharmacology
Volume23
Issue number1
DOIs
Publication statusPublished - Jan 1989
Externally publishedYes

Fingerprint

Mitoxantrone
Hepatitis B
Hepatocellular Carcinoma
Infection
Toxicity
Sinus Tachycardia
Heart Block
Fatal Outcome
Alopecia
Leukopenia
Stroke Volume
Nausea
Vomiting
Anemia
Diarrhea
Fever
Survival

ASJC Scopus subject areas

  • Pharmacology
  • Oncology
  • Cancer Research

Cite this

Phase II study of mitoxantrone in unresectable primary hepatocellular carcinoma following hepatitis B infection. / Lai, Kwok Hung; Tsai, Yang Te; Lee, Shou Dong; Ng, Wai Wah; Teng, Ho Chung; Tam, Tseng Nip; Lo, Gin Ho; Lin, Han Chieh; Lin, Hwai Jeng; Wu, Jaw Ching; Lay, Chii Shyan; Wang, Sun Sang; Chan, Wing Kai.

In: Cancer Chemotherapy and Pharmacology, Vol. 23, No. 1, 01.1989, p. 54-56.

Research output: Contribution to journalArticle

Lai, KH, Tsai, YT, Lee, SD, Ng, WW, Teng, HC, Tam, TN, Lo, GH, Lin, HC, Lin, HJ, Wu, JC, Lay, CS, Wang, SS & Chan, WK 1989, 'Phase II study of mitoxantrone in unresectable primary hepatocellular carcinoma following hepatitis B infection', Cancer Chemotherapy and Pharmacology, vol. 23, no. 1, pp. 54-56. https://doi.org/10.1007/BF00258459
Lai, Kwok Hung ; Tsai, Yang Te ; Lee, Shou Dong ; Ng, Wai Wah ; Teng, Ho Chung ; Tam, Tseng Nip ; Lo, Gin Ho ; Lin, Han Chieh ; Lin, Hwai Jeng ; Wu, Jaw Ching ; Lay, Chii Shyan ; Wang, Sun Sang ; Chan, Wing Kai. / Phase II study of mitoxantrone in unresectable primary hepatocellular carcinoma following hepatitis B infection. In: Cancer Chemotherapy and Pharmacology. 1989 ; Vol. 23, No. 1. pp. 54-56.
@article{527da3a39b514e5391c081c27c0feb2d,
title = "Phase II study of mitoxantrone in unresectable primary hepatocellular carcinoma following hepatitis B infection",
abstract = "A total of 20 patients with histologically proven primary hepatocellular carcinoma (PHC) received mitoxantrone IV at a dose of 10-16 mg/m2 every 3 weeks. All patients had previous hepatitis B infection. None underwent remission after treatment; 2 had stable disease and 18 progressive disease. The median overall survival was 13 weeks (range, 1-59 weeks). There was no evidence of significant antitumor activity for mitoxantrone in our patients with PHC. Hematotoxicity occurred in 100{\%} of the patients with grades 2-4 leukopenia, 89{\%} of those with grades 1-4 anemia, and 26{\%} of those with grades 2-3 thrombocytopenia. Cardiotoxicity occurred in 20{\%} of the patients after 14-30 mg/m2 mitoxantrone; these included complete heart block with fatal outcome in one case, decreased ventricular ejection fraction in one, and sinus tachycardia in two. Nausea, vomiting, fever, diarrhea, and alopecia were mild and occurred in 15{\%}-45{\%} of the patients (Table 3). Therefore, patients with PHC following hepatitis B infection may be less tolerant to mitoxantrone, resulting in the apparent increase in toxicities.",
author = "Lai, {Kwok Hung} and Tsai, {Yang Te} and Lee, {Shou Dong} and Ng, {Wai Wah} and Teng, {Ho Chung} and Tam, {Tseng Nip} and Lo, {Gin Ho} and Lin, {Han Chieh} and Lin, {Hwai Jeng} and Wu, {Jaw Ching} and Lay, {Chii Shyan} and Wang, {Sun Sang} and Chan, {Wing Kai}",
year = "1989",
month = "1",
doi = "10.1007/BF00258459",
language = "English",
volume = "23",
pages = "54--56",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "1",

}

TY - JOUR

T1 - Phase II study of mitoxantrone in unresectable primary hepatocellular carcinoma following hepatitis B infection

AU - Lai, Kwok Hung

AU - Tsai, Yang Te

AU - Lee, Shou Dong

AU - Ng, Wai Wah

AU - Teng, Ho Chung

AU - Tam, Tseng Nip

AU - Lo, Gin Ho

AU - Lin, Han Chieh

AU - Lin, Hwai Jeng

AU - Wu, Jaw Ching

AU - Lay, Chii Shyan

AU - Wang, Sun Sang

AU - Chan, Wing Kai

PY - 1989/1

Y1 - 1989/1

N2 - A total of 20 patients with histologically proven primary hepatocellular carcinoma (PHC) received mitoxantrone IV at a dose of 10-16 mg/m2 every 3 weeks. All patients had previous hepatitis B infection. None underwent remission after treatment; 2 had stable disease and 18 progressive disease. The median overall survival was 13 weeks (range, 1-59 weeks). There was no evidence of significant antitumor activity for mitoxantrone in our patients with PHC. Hematotoxicity occurred in 100% of the patients with grades 2-4 leukopenia, 89% of those with grades 1-4 anemia, and 26% of those with grades 2-3 thrombocytopenia. Cardiotoxicity occurred in 20% of the patients after 14-30 mg/m2 mitoxantrone; these included complete heart block with fatal outcome in one case, decreased ventricular ejection fraction in one, and sinus tachycardia in two. Nausea, vomiting, fever, diarrhea, and alopecia were mild and occurred in 15%-45% of the patients (Table 3). Therefore, patients with PHC following hepatitis B infection may be less tolerant to mitoxantrone, resulting in the apparent increase in toxicities.

AB - A total of 20 patients with histologically proven primary hepatocellular carcinoma (PHC) received mitoxantrone IV at a dose of 10-16 mg/m2 every 3 weeks. All patients had previous hepatitis B infection. None underwent remission after treatment; 2 had stable disease and 18 progressive disease. The median overall survival was 13 weeks (range, 1-59 weeks). There was no evidence of significant antitumor activity for mitoxantrone in our patients with PHC. Hematotoxicity occurred in 100% of the patients with grades 2-4 leukopenia, 89% of those with grades 1-4 anemia, and 26% of those with grades 2-3 thrombocytopenia. Cardiotoxicity occurred in 20% of the patients after 14-30 mg/m2 mitoxantrone; these included complete heart block with fatal outcome in one case, decreased ventricular ejection fraction in one, and sinus tachycardia in two. Nausea, vomiting, fever, diarrhea, and alopecia were mild and occurred in 15%-45% of the patients (Table 3). Therefore, patients with PHC following hepatitis B infection may be less tolerant to mitoxantrone, resulting in the apparent increase in toxicities.

UR - http://www.scopus.com/inward/record.url?scp=0024581695&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024581695&partnerID=8YFLogxK

U2 - 10.1007/BF00258459

DO - 10.1007/BF00258459

M3 - Article

VL - 23

SP - 54

EP - 56

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 1

ER -